FBRX · As filed with the SEC
Forte Biosciences cash flow statement, by quarter
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | — | — | — | — | (15,656,000) | — | — |
| Net loss | — | (22,136,000) | — | — | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | — | 19,000 | — | — | — | 13,000 | — | — |
| Stock-based compensation expense | — | 3,177,000 | — | — | — | 1,620,000 | — | — |
| Accretion of debt discount on available-for-sale securities | — | — | — | — | — | — | — | 9,000† |
| Accretion of debt discount on available-for-sale securities | — | (7,000) | — | — | — | (240,000) | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | — | (3,197,000) | — | — | — | 1,641,000 | — | — |
| Accounts payable | — | 3,095,000 | — | — | — | 578,000 | — | — |
| Accrued liabilities | — | (198,000) | — | — | — | 1,689,000 | — | — |
| Other liabilities | — | 439,000 | — | — | — | — | — | — |
| Net cash used in operating activities | — | (18,808,000) | — | — | — | (10,355,000) | — | — |
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | — | 0 | — | — | — | (61,000) | — | — |
| Proceeds from redemptions of short-term investments | — | 0 | — | — | — | 36,350,000 | — | — |
| Net cash (used in) provided by investing activities | — | 0 | — | — | — | 36,289,000 | — | — |
| Cash flows from financing activities: | ||||||||
| Payment of issuance costs associated with financings | — | 0 | — | — | — | (2,316,000) | — | — |
| Proceeds from issuance of common stock under ESPP | — | 101,000 | — | — | — | 9,000 | — | — |
| Taxes paid related to net share settlement of equity awards | — | (27,000) | — | — | — | (15,000) | — | — |
| Net cash provided by financing activities | — | 74,000 | — | — | — | (2,322,000) | — | — |
| Net (decrease) increase in cash and cash equivalents | — | (18,734,000) | — | — | — | 23,612,000 | — | — |
| Cash and cash equivalents — beginning of period | 58,223,000 | 76,957,000 | 93,414,000 | 106,144,000 | 45,856,000 | 22,244,000 | 16,363,000 | 24,498,000 |
| Cash and cash equivalents — end of period | 49,629,000 | 58,223,000 | 76,957,000 | 93,414,000 | 106,144,000 | 45,856,000 | 22,244,000 | 16,363,000 |
| Supplemental disclosure of non-cash investing and financing activities | ||||||||
| Unpaid issuance costs recorded in accounts payable and accrued liabilities | — | 41,000 | — | — | — | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.